Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE.
Laroni A, et al. Among authors: sormani mp.
J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16.
J Neuroimmune Pharmacol. 2012.
PMID: 22585413